comparemela.com
6
7
8
9
10
11
12
Latest Breaking News On - Ipilimumab - Page 5 : comparemela.com
Treating Patients with High-Risk Melanoma
A comprehensive overview of treatment approaches for patients with high-risk melanoma.
Nikhil-khushalani
Annac-pavlick
Sunandana-chandra
Unresectable-metastatic-melanoma
High-risk-melanoma
Ipilimumab
Anti-pd-1
Braf-mek
Stage-iii-disease
Resected-stage-iv
Pembrolizumab
Deciding Between Melanoma Therapy Options
A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.
Sunandana-chandra
Annac-pavlick
Nikhil-khushalani
Unresectable-metastatic-melanoma
Combination-immunotherapy
Toxicity
Ipilimumab
Nivolumab
Anti-pd-1
Braf-mutations
Triplet-therapy
BRAF/MEK Dual Inhibitors for Melanoma
An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.
Sunandana-chandra
Nikhil-khushalani
Clinical-oncology
Unresectable-metastatic-melanoma
Dreamseq-trial
Combination-immunotherapy
Braf-mek
Targeted-therapy
Second-line-treatment
Ipilimumab
Nivolumab
Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in Melanoma
Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.
Diane-nye
Michael-rayden
Clairef-verschraegen
Ohio-state-university-college-of-medicine
Ohio-state-university-comprehensive-cancer-center
Division-of-medical-oncology
Innovative-cancer-research
Medical-oncology
Ohio-state-university-college
Melanoma-amp-skin-cancer
News
Immunotherapy
Considerations in Advanced RCC Treatment Selection
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.
United-states
American
Benjamin-garmezy
Pedro-barata
Sloan-kettering
Memorial-sloan-kettering
African-american
Renal-cell-carcinoma
Io-tkis
Immunotherapy
Sunitinib
vimarsana © 2020. All Rights Reserved.